“…As stated above, ruxolitinib doses and timing of administration greatly influence the immune state, the subsequent pathogen clearance and survival [84]. Besides, a withdrawal syndrome is described when patients cease ruxolitinib treatment, which is termed "ruxolitinib discontinuation syndrome" and can lead to a cytokine storm that could be highly detrimental in a context of sepsis [89].…”